In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

The American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly ...

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

Erik Paulsen is the chairman of the Institute for Gene Therapies and a former Member of Congress (MN-3), serving from 2009 to ...

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher ...

Drug production is expected to be one of the main drivers of employment growth in U.S. manufacturing through 2034, with the ...

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous ...

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...